December 2020 • PharmaTimes Magazine • 4-5
Injecting the lightning bolt of digital into the relentless ambition of pharma has created a portal into the future, and not a moment too soon, finds John Pinching
Leslie Galloway looks back over 2020, outlining the challenges faced by the life sciences sector and the potential opportunities that lie ahead
Oli Hudson explores the changes that have occurred in the NHS this year as the Long Term Plan has been rolled out at speed in response to the COVID crisis
As mega deals slow, private capital becomes the driving force behind 2020 M&A, says Tom Cowap
Jenny Ousbey outlines the patient experience and developments in advocacy
David Gwyn explores what 2020 has taught the pharma industry about the necessity of transforming regulatory information management
The Royal Society of Chemistry's Richard Kidd explains why better databases are key to chemistry's digital future
Novo Nordisk's Dr Jan Westerink outlines findings from a pooled analysis of data from the SUSTAIN 6 and PIONEER 6 trials
Syneos Health's Ewan Cutherbertson on lessons for biopharma marketers during COVID-19
45.
Appointments